Advertisement

Surgery Versus Observation for Papillary Thyroid Microcarcinoma

  • Shi Lam
  • Brian H. H. Lang
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Papillary thyroid carcinoma (PTC) is the most common malignancy arising from the follicular cells and its age-adjusted incidence has doubled over the past two decades. As a result, it imposes a cost burden to the society in general. However, despite the rapid rise in incidence, the actual mortality (or the chance of dying) from PTC has remained relatively unchanged in the same period.

Keywords

Papillary thyroid carcinoma (PTC) Papillary thyroid microcarcinoma (PTMC) 

References

  1. 1.
    Lang BH, Wong KH, Chan CT. Initial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: a health care service provider perspective. Eur J Surg Oncol. 2015;41(6):758–65.  https://doi.org/10.1016/j.ejso.2015.01.019.CrossRefPubMedGoogle Scholar
  2. 2.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Pacini F. Thyroid microcarcinoma. Best Pract Res Clin Endocrinol Metab. 2012;26:421–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Yokozawa T, Miyauchi A, Kuma K, et al. Accurate and simple method of diagnosing thyroid nodules the modified technique of ultrasound-guided fine needle aspiration biopsy. Thyroid. 1995;5:141–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Takebe K, Date M, Yamamoto Y, et al. Mass screening for thyroid cancer with ultrasonography. Karkinos. 1994;7:309–17.Google Scholar
  6. 6.
    Cancer incidence and mortality in Hong Kong 1983–2011. Hong Kong Cancer Registry, Hong Kong. http://www3.ha.org.hk/cancereg/. Accessed 12 Mar 2015.
  7. 7.
    Ito Y, Uruno R, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid gland. Thyroid. 2003;13:381–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Lo CY, Chan WF, Lang BH, et al. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg. 2006;30:759–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254:653–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol. 2015;27:15–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sugitani I, Fujimoto Y, Yamada K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg. 2014;38:673–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007;14(2):730–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Miyauchi A, Kudo T, Kihara M, et al. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J. 2013;60:415–21.PubMedGoogle Scholar
  17. 17.
    Lang BH, Lo CY, Wong KP, Wan KY. Long-term outcomes for older patients with papillary thyroid carcinoma: should another age cutoff beyond 45 years be added? Ann Surg Oncol. 2015;22(2):446–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be observed? A word of caution. Arch Otolaryngol Head Neck Surg. 2010;136:444–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Takami H, Ito Y, Okamoto T, et al. Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg. 2014;38:2002–10.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryThe University of Hong KongHong Kong SARChina
  2. 2.Division of Endocrine Surgery, Department of SurgeryQueen Mary HospitalHong Kong SARChina

Personalised recommendations